NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Welbilt, Inc. (NYSE: WBT) Class Period: February 24, 2017 - November 2, 2018 Lead Plaintiff Deadline: February 11, 2019 Join the action: https://www.zlk.com/pslra-1/welbilt-inc-loss-form?wire=3
About the lawsuit: During the class period, Welbilt, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal control over financial reporting; (ii) the Company was incorrectly recording the tax basis of foreign subsidiaries and the amortization of their intangible assets; and (iii) as a result of the foregoing, Defendants’ statements about Welbilt’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. On November 5, 2018, Welbilt filed a Form 8-K for its Q3 2018, stating that “During the third quarter of 2018, the Company identified errors in the tax basis of a foreign subsidiary and incorrect amortization of the intangible assets held by the same entity… In addition, the Company discovered certain intercompany transactions were not recorded on a timely basis.” As a result of these errors, Welbilt announced that “the consolidated financial statements of the Company as of and for the year ended December 31, 2016 will be restated, and as of and for the years ended December 31, 2015 and 2017 are expected to be revised.”
To learn more about the Welbilt, Inc. class action contact jlevi@levikorsinsky.com .
DBV Technologies S.A. (NASDAQ: DBVT) Class Period: February 14, 2018 - December 19, 2018 Lead Plaintiff Deadline: March 18, 2019 Join the action: https://www.zlk.com/pslra-1/dbv-technologies-...orm?wire=3
About the lawsuit: Throughout the class period, DBV Technologies S.A. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) DBV Technologies' Biologics License Application ("BLA") for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls; (2) consequently, DBV Technologies voluntarily withdrew the BLA for Viaskin Peanut; and (3) as a result, defendants' statements about DBV Technologies' business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the DBV Technologies S.A. class action contact jlevi@levikorsinsky.com .
Astec Industries, Inc. (NASDAQ: ASTE) Class Period: July 26, 2016 - October 22, 2018 Lead Plaintiff Deadline: April 2, 2019 Join the action: https://www.zlk.com/pslra-1/astec-industries-...orm?wire=3
The complaint alleges that throughout the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information regarding Astec’s business, operations and prospects, including that its wood pellet plants suffered from significant and costly problems that prevented them from running at their promised production capacity, posing a threat to the Company’s pellet plant business, its overall financial performance, and its financial outlook. As a result of this information being withheld from the market, the price of Astec stock was artificially inflated to a high of nearly $70 per share during the Class Period.
To learn more about the Astec Industries, Inc. class action contact jlevi@levikorsinsky.com .
Tyme Technologies, Inc. (NASDAQCM: TYME) Class Period: March 14, 2018 - January 18, 2019 Lead Plaintiff Deadline: March 29, 2019 Join the action: https://www.zlk.com/pslra-1/tyme-technologies...orm?wire=3
About the lawsuit: Tyme Technologies, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (iv) as a result, Tyme’s public statements were materially false and misleading at all relevant times.
To learn more about the Tyme Technologies, Inc. class action contact jlevi@levikorsinsky.com .
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 55 Broadway, 10th Floor New York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
